Is RANKL inhibition both anti-resorptive and anabolic in rheumatoid arthritis?

Natalie A. Sims1,2* and Evange Romas2,3

See related research by Kato et al. http://www.arthritis-research.com/content/17/1/251

Abstract

A small peptide, OP3-4, blocks receptor activator of NF-κB from binding to its ligand, receptor activator of NF-κB ligand (RANKL), and was reported recently to inhibit bone resorption, promote bone formation and protect cartilage in a preclinical rheumatoid arthritis model. The latter effects may result from inhibition of RANKL reverse signalling in osteoblasts and chondrocytes. Whether other RANKL inhibitors, such as denosumab, share this action is not known, but OP3-4 at least has potential to provide anabolic treatment for both systemic and focal bone loss in inflammatory arthritis.

Editorial

In a recent article in Arthritis Research and Therapy, Kato et al. [1] report anabolic action of a novel inhibitor of receptor activator of NF-κB ligand (RANKL) in a preclinical rheumatoid arthritis (RA) model.

Elevated osteoclast formation in RA occurs in two contexts: local osteoclastogenesis causing joint erosion and periarticular bone loss fuelled by tumour necrosis factor alpha (TNFα) and RANKL; and systemic bone resorption resulting in generalized osteoporosis [2].

To achieve low RA disease activity or remission, RA treatment must rapidly suppress inflammatory synovitis, initially with disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and, if needed, followed by antibody-based biological agents, such as TNFα or interleukin (IL)-6 inhibitors (e.g. tocilizumab). The extent to which joint structure is protected from bone erosion with methotrexate correlates with synovitis suppression. In contrast, TNFα or IL-6 inhibitors abolish osteoclast-mediated bone erosion even with residual synovial inflammation, because IL-6 and TNFα stimulate osteoclast differentiation [2].

Osteoporosis in RA correlates with disease severity. Although bone loss may be prevented by treatment with methotrexate and TNFα inhibitors, bone antiresorptive therapy, specifically targeting osteoclasts, is often required to prevent fragility fractures [2]. Generally, weaker antiresorptives such as alendronate may preserve bone mineral density but do not prevent articular bone erosions. In contrast, zoledronate and RANKL inhibitors, such as denosumab, reduce osteoclast numbers, arresting both local erosion and systemic bone loss in preclinical models [3, 4] and in RA patients [5, 6]. These agents are not registered as DMARDs and denosumab has not generally been combined with biological DMARDs due to infection concerns. However, the hospitalized infection rate among RA patients receiving denosumab concurrently with biological DMARDs is no greater than in those receiving zoledronate [7].

Denosumab and zoledronate not only reduce bone resorption, but also inhibit serum bone formation markers in women with osteoporosis [8, 9]. This reflects a major function of osteoclasts beyond bone resorption: the production of ‘coupling factors’ and ‘osteo-transmitters’ that promote bone formation on trabecular [10] and periosteal [11] surfaces, respectively. Increased bone mineral density observed during sustained osteoclast inhibition has therefore been thought to result not from increased bone formation, but from continued secondary mineralization in the absence of bone resorption [12].

The novel RANKL inhibitor used by Kato et al. [1] not only reduced bone resorption but also promoted bone formation and suppressed cartilage loss, suggesting a positive local effect on bone formation. This questions whether secondary mineralization is the only contributor to increased bone mineral density observed with RANKL inhibition.
The possibility that RANKL inhibition could promote bone formation was first identified when W9, a small molecule inhibitor of RANK-RANKL binding, not only impaired osteoclastogenesis but also promoted osteoblast differentiation in vitro, and stimulated cortical bone formation in vivo [13]. Follow-up studies in RANKL-deficient osteoblasts suggested that ‘outside-in’ or ‘reverse’ intra-cellular RANKL signalling within osteoblast precursors inhibits their differentiation [13]. Kato et al. [1] report that OP3-4, which also binds RANKL, not only inhibits bone resorption but increases bone formation in the collagen-induced arthritis model. This was particularly evident in the epiphysis, where local bone formation levels were low. OP3-4 also inhibited osteoblast differentiation in vitro [1]. Since hypertrophic chondrocytes express RANKL [14], OP3-4 may protect against cartilage destruction by inhibiting reverse RANKL signalling; preliminary data in a chondrocyte cell line are shown.

The precise mechanisms by which OP3-4 elicits an osteoblastic anabolic response via reverse RANKL signalling remain to be defined. It will also be important to determine whether OP3-4 promotes bone formation systemically, in specific locations (e.g. cortical or trabecular bone) or only in apposition to focal erosions in arthritis. From a clinical perspective, interaction of RANKL inhibition with anti-inflammatory approaches (including both synthetic small molecule and biological DMARDs) must be established.

Finally, a major question is whether the ability of OP3-4 and W9 to promote bone formation is shared with antibodies to RANKL such as denosumab. The current evidence suggests that this property is unique to the OP3-4 and W9 peptides. Recent histomorphometry in denosumab-treated cynomolgus monkeys showed that denosumab neither reduces bone modelling (bone formation on surfaces that have not been resorbed previously), nor stimulates bone formation [15].

Targeting RANKL to treat bone loss in inflammatory arthritis could provide more benefit than simply inhibiting resorption. Kato et al. highlight additional effects to promote bone formation and protect cartilage that deserve additional study.

Abbreviations

DMARD: Disease-modifying antirheumatic drug; IL: Interleukin; RA: Rheumatoid arthritis; RANKL: Receptor activator of NF-κB ligand; TNFα: Tumour necrosis factor alpha.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

NAS and ER wrote, edited and approved the final manuscript.

Author details

1St. Vincent’s Institute of Medical Research, 9 Princes Street, Fitzroy, VIC 3065, Australia. 2Department of Medicine at St. Vincent’s Hospital Melbourne, The University of Melbourne, 41 Victoria Pde, Fitzroy, VIC 3065, Australia.

References

1. Kato G, Shimizu Y, Arai Y, Suzuki N, Sugamori Y, Maeda M, et al. The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. Arthritis Res Ther. 2015;17:251.
2. Schett G, Gravellese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8:656–64.
3. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, et al. Osteoprogerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol. 2002;161:1419–27.
4. Sims NA, Green JR, Grant M, Schlict S, Martin TJ, Gillespie MT, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum. 2004;50:2338–46.
5. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299–309.
6. Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O’Connor PJ, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 2006;54:1410–4.
7. Curtis JR, Xie F, Yun H, Saag KG, Chen L, Delzel E. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol. 2015;67:1456–64.
8. Reid JR, Miller PD, Brown JP, Kendler DL, Faehlmeier-Pannner A, Valter I, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010;25:2256–65.
9. Back DM, Delmas PD, Ealet R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.
10. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005;11:76–81.
11. Johnson RW, McGregor NE, Brennan HJ, Cimteen-Inniv B, Poulton L, Martin TJ, et al. Glycoprotein130 (Gp130)/interleukin-6 (IL-6) signalling in osteoclasts promotes bone formation in periosteal and trabecular bone. Bone. 2015;81:343–51.
12. Sims NA, Nij KW. Implications of osteoblast–osteoclast interactions in the management of osteoporosis by anti-sresorptive agents denosumab and odanacatib. Curr Osteoporos Rep. 2014;12:98–106.
13. Furuya Y, Inagaki A, Khan M, Mori K, Pennington JM, Nakamura M, et al. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-kappaB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J Biol Chem. 2012;287:6562–71.
14. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM, et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999;25:525–34.
15. Ominsky MS, Libanati C, Niou Q-T, Boyce RW, Kostenuik PJ, Wagnman RB, et al. Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res. 2015;30:1280–9.